
Sign up to save your podcasts
Or


The editors also review the evidence for cladribine for the treatment of highly active relapsing multiple sclerosis (http://dtb.bmj.com/content/56/2/21) and discuss the latest levonorgestrel IUS device to be marketed for contraception (http://dtb.bmj.com/content/56/2/18).
By BMJ Group4.8
44 ratings
The editors also review the evidence for cladribine for the treatment of highly active relapsing multiple sclerosis (http://dtb.bmj.com/content/56/2/21) and discuss the latest levonorgestrel IUS device to be marketed for contraception (http://dtb.bmj.com/content/56/2/18).

890 Listeners

221 Listeners

36 Listeners

48 Listeners

7 Listeners

6 Listeners

3 Listeners

1 Listeners

3 Listeners

10 Listeners

40 Listeners

14 Listeners

1 Listeners

50 Listeners

0 Listeners

6 Listeners

16 Listeners

85 Listeners

71 Listeners

236 Listeners

18 Listeners

3 Listeners

19 Listeners

23 Listeners

52 Listeners

11 Listeners

8 Listeners

23 Listeners

4 Listeners

2,073 Listeners

6 Listeners

0 Listeners